RESEARCH ARTICLE
The Efficacy of Continued Sorafenib Treatment after Radiologic Confirmation of Progressive Disease in Patients with Advanced Hepatocellular Carcinoma Yoshiyuki Wada*☯, Yuko Takami☯, Masaki Tateishi☯, Tomoki Ryu☯, Kazuhiro Mikagi☯, Hideki Saitsu☯ Department of Hepato-Biliary-Pancreatic Surgery, Clinical Research Institute, National Hospital Organization Kyushu Medical Center, Fukuoka, Japan ☯ These authors contributed equally to this work. * [email protected]
Abstract Background OPEN ACCESS Citation: Wada Y, Takami Y, Tateishi M, Ryu T, Mikagi K, Saitsu H (2016) The Efficacy of Continued Sorafenib Treatment after Radiologic Confirmation of Progressive Disease in Patients with Advanced Hepatocellular Carcinoma. PLoS ONE 11(1): e0146456. doi:10.1371/journal.pone.0146456 Editor: Teh-Ia Huo, Taipei Veterans General Hospital, TAIWAN Received: November 5, 2015 Accepted: December 17, 2015
Whether radiologically detected progressive disease (PD) is an accurate metric for discontinuing sorafenib treatment in patients with hepatocellular carcinoma (HCC) is unclear. We investigated the efficacy of sorafenib treatment after radiologic confirmation of PD in patients with advanced HCC.
Methods We retrospectively analyzed HCC patients treated with sorafenib at Kyushu Medical Center. Six of the 92 patients with radiologically confirmed PD were excluded because they were classified as Child-Pugh C or had an Eastern Cooperative Oncology Group (ECOG) performance status (PS) 3; 86 patients were ultimately enrolled.
Published: January 8, 2016 Copyright: © 2016 Wada et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. Data Availability Statement: All relevant data are within the paper and its Supporting Information files. Funding: The authors have no support or funding to report. Competing Interests: The authors have declared that no competing interests exist.
Results Among the 86 patients, 47 continued sorafenib treatment after radiologic confirmation of PD (the continuous group), whereas 39 did not (the discontinuous group). The median survival time (MST) in the continuous group after confirmation was 12.9 months compared with 4.5 months in the discontinuous group (p
The Efficacy of Continued Sorafenib Treatment after Radiologic Confirmation of Progressive Disease in Patients with Advanced Hepatocellular Carcinoma Yoshiyuki Wada*☯, Yuko Takami☯, Masaki Tateishi☯, Tomoki Ryu☯, Kazuhiro Mikagi☯, Hideki Saitsu☯ Department of Hepato-Biliary-Pancreatic Surgery, Clinical Research Institute, National Hospital Organization Kyushu Medical Center, Fukuoka, Japan ☯ These authors contributed equally to this work. * [email protected]
Abstract Background OPEN ACCESS Citation: Wada Y, Takami Y, Tateishi M, Ryu T, Mikagi K, Saitsu H (2016) The Efficacy of Continued Sorafenib Treatment after Radiologic Confirmation of Progressive Disease in Patients with Advanced Hepatocellular Carcinoma. PLoS ONE 11(1): e0146456. doi:10.1371/journal.pone.0146456 Editor: Teh-Ia Huo, Taipei Veterans General Hospital, TAIWAN Received: November 5, 2015 Accepted: December 17, 2015
Whether radiologically detected progressive disease (PD) is an accurate metric for discontinuing sorafenib treatment in patients with hepatocellular carcinoma (HCC) is unclear. We investigated the efficacy of sorafenib treatment after radiologic confirmation of PD in patients with advanced HCC.
Methods We retrospectively analyzed HCC patients treated with sorafenib at Kyushu Medical Center. Six of the 92 patients with radiologically confirmed PD were excluded because they were classified as Child-Pugh C or had an Eastern Cooperative Oncology Group (ECOG) performance status (PS) 3; 86 patients were ultimately enrolled.
Published: January 8, 2016 Copyright: © 2016 Wada et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. Data Availability Statement: All relevant data are within the paper and its Supporting Information files. Funding: The authors have no support or funding to report. Competing Interests: The authors have declared that no competing interests exist.
Results Among the 86 patients, 47 continued sorafenib treatment after radiologic confirmation of PD (the continuous group), whereas 39 did not (the discontinuous group). The median survival time (MST) in the continuous group after confirmation was 12.9 months compared with 4.5 months in the discontinuous group (p
